Figure 6. Evidence of anti-leukemic activity.

(A) Percent WT1-specific multimer⁺ cells detected in PBMC (solid black circles, black line) of Pt 15 after infusion of 3.3 × 10⁹ cells/m² (left y-axis), concurrent percent leukemic blasts in the blood (red area) (inner right y-axis). Total white blood cells (solid grey line) and lymphocytes (dashed grey line) (outer right y-axis) in samples collected before and after the infusion (x-axis). (B) Percent multimer⁺CD8⁺ T-cells (y-axis) among PBMCs (solid circles) and in BM (open circles) collected before and after infusions for Pt 27. Arrows indicate time of infusions. Below the graph are characteristics of the patient’s primary B-ALL at diagnosis (left, below B-ALL), and at timepoints at which clonal B cells or the abnormal karyotype were analyzed and detected (+) in BM. (C) Mean effective concentrations of peptide required to achieve 50% lysis (EC₅₀₎ of pulsed T2 BLCL at an effector to target ratio (E:T) of 10:1 by the CTL clones infused for each patient.